Literature DB >> 28340864

Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment.

Jolene H Fisher1, Faris Al-Hejaili2, Sonja Kandel3, Alim Hirji1, Shane Shapera1, Marco Mura4.   

Abstract

BACKGROUND: The heterogeneous progression of idiopathic pulmonary fibrosis (IPF) makes prognostication difficult and contributes to high mortality on the waitlist for lung transplantation (LTx). Multi-dimensional scores (Composite Physiologic index [CPI], [Gender-Age-Physiology [GAP]; RIsk Stratification scorE [RISE]) demonstrated enhanced predictive power towards outcome in IPF. The lung allocation score (LAS) is a multi-dimensional tool commonly used to stratify patients assessed for LTx. We sought to investigate whether IPF-specific multi-dimensional scores predict mortality in patients with IPF assessed for LTx.
METHODS: The study included 302 patients with IPF who underwent a LTx assessment (2003-2014). Multi-dimensional scores were calculated. The primary outcome was 12-month mortality after assessment. LTx was considered as competing event in all analyses.
RESULTS: At the end of the observation period, there were 134 transplants, 63 deaths, and 105 patients were alive without LTx. Multi-dimensional scores predicted mortality with accuracy similar to LAS, and superior to that of individual variables: area under the curve (AUC) for LAS was 0.78 (sensitivity 71%, specificity 86%); CPI 0.75 (sensitivity 67%, specificity 82%); GAP 0.67 (sensitivity 59%, specificity 74%); RISE 0.78 (sensitivity 71%, specificity 84%). A separate analysis conducted only in patients actively listed for LTx (n = 247; 50 deaths) yielded similar results.
CONCLUSIONS: In patients with IPF assessed for LTx as well as in those actually listed, multi-dimensional scores predict mortality better than individual variables, and with accuracy similar to the LAS. If validated, multi-dimensional scores may serve as inexpensive tools to guide decisions on the timing of referral and listing for LTx.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Interstitial lung disease; Lung transplantation; Survival

Mesh:

Year:  2017        PMID: 28340864     DOI: 10.1016/j.rmed.2017.03.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

1.  Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?

Authors:  Karishma Hosein; Jamie Le; Marco Mura
Journal:  Lung       Date:  2016-11-17       Impact factor: 2.584

2.  The CALIPER-Revised Version of the Composite Physiologic Index is a Better Predictor of Survival in IPF than the Original Version.

Authors:  Karishma S Hosein; Gianluigi Sergiacomi; Maurizio Zompatori; Marco Mura
Journal:  Lung       Date:  2019-12-02       Impact factor: 2.584

3.  Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial.

Authors:  Gian Marco Manzetti; Karishma Hosein; Matthew J Cecchini; Keith Kwan; Mohamed Abdelrazek; Maurizio Zompatori; Paola Rogliani; Marco Mura
Journal:  BMC Pulm Med       Date:  2021-12-04       Impact factor: 3.317

Review 4.  Lung Transplantation in Idiopathic Pulmonary Fibrosis.

Authors:  Rosalía Laporta Hernandez; Myriam Aguilar Perez; María Teresa Lázaro Carrasco; Piedad Ussetti Gil
Journal:  Med Sci (Basel)       Date:  2018-08-23

5.  Comparison of disease progression subgroups in idiopathic pulmonary fibrosis.

Authors:  Miia Kärkkäinen; Hannu-Pekka Kettunen; Hanna Nurmi; Tuomas Selander; Minna Purokivi; Riitta Kaarteenaho
Journal:  BMC Pulm Med       Date:  2019-11-29       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.